Search

Displaying results 731 - 740 of 4822 in total
  1. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. … It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.

  2. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. … It is a soluble plasma glycoprotein with a molecular weight of about 340 kDa and is a physiological substrate for three enzymes: plasmin, factor XIIIa, and thrombin.

  3. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    It was developed by The Medicines Company (acquired by Novartis). … It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.

  4. Drug

    Propoxycaine

    go.drugbank.com/drugs/DB09342
    Approved

    Used in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592].

  5. Drug

    Nisoldipine

    go.drugbank.com/drugs/DB00401
    Approved

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.

  6. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    It was first approved by the FDA in 1997 [L5882]. … It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867].

  7. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] It was developed by Global Blood Therapeutics, Inc. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition

  8. Drug

    Benzatropine

    go.drugbank.com/drugs/DB00245
    ApprovedInvestigational

    It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970.

  9. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]

  10. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it